pdl-2

Nivolumab 属于单克隆抗体，是一种人源化的 PD-1 的 IgG4 抗体。Nivolumab 具有抗肿瘤活性，被用于黑色素瘤、非小细胞肺癌、肾细胞癌等的治疗。

Cetrelimab (JNJ 63723283) 是一种抗 PD-1 的人源化单克隆抗体，剂量依赖性地增加 T 细胞介导的细胞因子产生并刺激细胞因子表达，可用于研究多发性骨髓瘤和膀胱癌。

Ezabenlimab (BI-754091) 是一种靶向程序性细胞死亡蛋白-1 的人源化单克隆抗体，具有抗肿瘤活性，可阻断 PD-1 与 PD-L1 和 PD-L2 的相互作用，抑制体内肿瘤生长，可用于研究晚期实体瘤。

The Immuno-Oncology Screening Library consists of 2 plates and contains more than 90 cancer and immunology-associated compounds in a 96-well Matrix tube rack format as 10 mM stock solutions in DMSO. This library includes a variety of immuno-oncology target modulators, including but not limited to, adenosine, CCR, CXCR, and TLR agonists and antagonists, BTK, PI3K, VEGFR, and BRAF inhibitors, PD-1/PDL-1 interaction inhibitors, and HDAC inhibitors. Please review the product insert for a full list of targets. Stability data is not available for the compounds as supplied in the screening library.